← Back to Search

Laser Therapy

LaseMD System for Melasma

N/A
Waitlist Available
Research Sponsored by LUTRONIC Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to days 30, 90 and 180 following last treatment.
Awards & highlights

Study Summary

This study will evaluate the clinical outcomes associated with use of the LaseMD Laser System for the treatment of melasma.

Eligible Conditions
  • Melasma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to days 30, 90 and 180 following last treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to days 30, 90 and 180 following last treatment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Clinician assessment of overall aesthetic improvement.
Improvement in the Melasma Area and Severity Index (MASI) from Baseline
Improvement in the Melasma Quality of Life Scale (MELASQOL) from baseline
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: LaseMD SystemExperimental Treatment1 Intervention
Subjects will receive LaseMD System treatment(s) for treatment of melasma.

Find a Location

Who is running the clinical trial?

LUTRONIC CorporationLead Sponsor
13 Previous Clinical Trials
551 Total Patients Enrolled
2 Trials studying Melasma
79 Patients Enrolled for Melasma
Kari Larson, MBAStudy DirectorSponsor GmbH
7 Previous Clinical Trials
416 Total Patients Enrolled
1 Trials studying Melasma
39 Patients Enrolled for Melasma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
LaseMD System for the Treatment of Melasma
2018. "LaseMD System for the Treatment of Melasma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03456674.
All > Melasma
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top